Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

European Journal of Cancer

Volumn 45, Issue 11, 2009, Pages 1959-1968

  George, S ^a   Blay, J Y ^b,c   Casali, P G ^d   Le Cesne, A ^e   Stephenson, P ^f   DePrimo, S E ^g   Harmon, C S ^g   Law, C N J ^g   Morgan, J A ^a   Ray Coquard, I ^b   Tassell, V ^g   Cohen, D P ^g   Demetri, G D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ LYON 1   (France)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f RHO INC   (United States)

^g PFIZER INC   (United States)

Author keywords

Continuous daily dosing; GIST; Receptor tyrosine kinases; Sunitinib; Targeted therapy

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; IMATINIB; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; LEUKOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; STOMATITIS; STROKE; THROMBOCYTE; THYROTROPIN BLOOD LEVEL; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VASCULAR FRAGILITY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 67249147869     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.02.011     Document Type: Article

References (25)

1. Miettinen M., and Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438 (2001) 1-12
2. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 (2004) 3813-3825
3. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
4. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 5708-5710
5. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 (2005) 5357-5364
6. Abrams T.J., Lee L.B., Murray L.J., et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2 (2003) 471-478
7. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
8. Murray L.J., Abrams T.J., Long K.R., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20 (2003) 757-766
9. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
10. Kim D.W., Jo Y.S., Jung H.S., et al. An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/PTC kinases. J Clin Endocrin Metab 91 (2006) 4070-4076
11. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
13. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE) version 3.0. Bethesda, MD: National Cancer Institute; 2003. .
14. Bello C.L., Sherman L., Zhou J., et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17 (2006) 353-358
15. Deprimo S.E., Bello C.L., Smeraglia J., et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5 (2007) 32
16. Demetri GD, Huang X, Garrett CR, et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) versus placebo (PL) in advanced GIST after imatinib (IM) failure [Abstract 35113]. Presented at: American Society of Clinical Oncology, 44th Annual Meeting, May 30-June 3, 2008, Chicago, IL.
17. ® (sunitinib malate) full prescribing information. .
18. Sica D.A. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 24 (2006) 1329-1331
19. Desai J., Yassa L., Marqusee E., et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 (2006) 660-664
20. Mannavola D., Coco P., Vannucchi G., et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92 (2007) 3531-3534
21. Wong E., Rosen L.S., Mulay M., et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17 (2007) 351-355
22. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 (2007) 81-83
23. George S, Blay JY, Casali PG, et al. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST [Abstract 10015]. Presented at: American Society of Clinical Oncology, 43rd Annual Meeting, June 1-5, 2007, Chicago, IL.
24. Norden-Zfoni A., Desai J., Manola J., et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13 (2007) 2643-2650
25. Blackstein M, Huang X, Demetri GD, et al. Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST [Abstract 10007]. Presented at: American Society of Clinical Oncology, 43rd Annual Meeting, June 1-5, 2007, Chicago, IL.